跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2014-002594-11-CZ
EUCTR2014-002594-11-CZ进行中（未招募）1 期

A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controlled focal seizures.

GW Research Ltd.0 个研究点目标入组 170 人开始时间: 2014年12月2日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
170
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Patient must be willing and able to give informed consent for participation in the study.
  • •Male or female aged between 18 and 65 years, inclusive.
  • •Well-documented history of focal epilepsy, with focal seizures as the primary seizure type, compatible electroencephalogram and clinical history.
  • •Documented CT/MRI that shows no progressive neurologic abnormality.
  • •Has focal seizures despite prior treatment with at least two AEDs (whether as monotherapies or in combination).
  • •Patient is willing to keep any factors expected to affect seizures stable (such as the level of alcohol consumption and smoking).
  • •Patient is able (in the investigators opinion) and willing to comply with all study requirements (including accurate diary completion).
  • •Patient is willing to allow his or her primary care practitioner and consultant to be notified of participation in the study.
  • •Part A only
  • •Currently treated with one to three AEDs as follows:
  • •Group 1 - including Carbamazepine, Phenobarbital, Primidone or Phenytoin and excluding Valproic Acid (VPA).
  • •Group 2 - including VPA and excluding Carbamazepine, Phenobarbital, Primidone and Phenytoin.
  • •Group 3 - excluding VPA, Carbamazepine, Phenobarbital, Primidone and Phenytoin.
  • •All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for two weeks prior to screening and the patient is willing to maintain a stable regimen throughout the study.
  • •Part B only
  • •Currently treated with one to three AEDs.
  • •All medications or interventions for epilepsy (including ketogenic diet) must have been stable for one month prior to screening and the patient is willing to maintain a stable regimen throughout the study.
  • •At the end of the baseline period patients must also meet the following criteria:
  • •- Complied with diary completion, having no more than three missed diary entries during baseline.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 166
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 4

排除标准

  • •Time of onset of epilepsy treatment is less than two years prior to enrolment.
  • •Episode(s) of status epilepticus during one year prior to screening.
  • •History of pseudo-seizures.
  • •Patient has clinically significant unstable medical conditions other than epilepsy.
  • •Patient has an illness in the four weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator would affect seizure frequency.
  • •Patient has, in the investigator’s opinion, clinically significantly abnormal laboratory values.
  • •In the opinion of the investigator the patient has clinically significant abnormalities in the 12-lead electrocardiogram (ECG) measured at screening or randomization or any concurrent cardiovascular conditions, which will interfere with the ability to read their ECGs.
  • •Active suicidal plan/intent in the past six months, or a history of suicide attempt in the last two years, or more than one lifetime suicide attempt.
  • •Patient has a history or presence of alcohol or substance abuse within the two years prior to screening or daily consumption of five or more alcohol-containing beverages.
  • •Patient is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid based medications within the three months prior to screening and is unwilling to abstain for the duration for the study.
  • •Patient has taken St John’s Wort in the two weeks prior to screening and/or is unwilling to abstain throughout the study.
  • •Any known or suspected hypersensitivity to cannabinoids, sesame oil or any of the excipients of the IMP(s).
  • •Female patients of child bearing potential and male patients whose partner is of child bearing potential, unless willing to ensure that they and/or their partner use a highly effective method of contraception.
  • •Female patient who is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.
  • •Patients who have received an IMP within the 12 weeks prior to the screening visit.
  • •Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, may influence the result of the study, or the patient’s ability to participate in the study.
  • •Following a physical examination, the patient has any abnormalities that, in the opinion of the investigator would prevent the patient from safe participation in the study.
  • •Unwilling to abstain from donation of blood during the study.
  • •Travel outside the country of residence planned during the study.
  • •Patients previously randomized into this study.
  • •Patient has consumed grapefruit or grapefruit juice three days prior to randomization and/or unwilling to abstain in the three days prior to PK sampling visits.
  • •Part A only
  • •Patient has significantly impaired hepatic function at Visit 1 (ALT >5 x ULN or TBL >2 x ULN) OR the ALT or AST >3 x ULN and TBL >2 x ULN (or INR >1.5).
  • •Part B only
  • •Patient has significantly impaired hepatic function at Visit 1 defined as any of the following:
  • •- ALT or AST >5 × ULN.
  • •- ALT or AST >3 × ULN and TBL >2 × ULN.
  • •-ALT or AST >3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
  • •Vagus Nerve Stimulation, Deep Brain Stimulation, Responsive Neurostimulator System or other epilepsy neurostimulation device have been implanted or activated less than one year prior to screening, and/

研究者

发起方
GW Research Ltd.

相似试验

进行中（未招募）
1 期
A study of GWP42006 in people with focal seizuresEpilepsy
EUCTR2014-002594-11-ESGW Research Ltd.130
进行中（未招募）
1 期
A study of GWP42006 in people with focal seizuresMedDRA version: 19.0 Level: LLT Classification code 10016843 Term: Focal seizures System Organ Class: 100000004852Epilepsy
EUCTR2014-002594-11-GBGW Research Ltd.194
进行中（未招募）
1 期
A study of GWP42006 in people with focal seizuresMedDRA version: 19.0Level: LLTClassification code 10016843Term: Focal seizuresSystem Organ Class: 100000004852Epilepsy
EUCTR2014-002594-11-HUGW Research Ltd.170
进行中（未招募）
1 期
A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (TLESRs) in GERD patients with incomplete response to PPI - n.a.Gastroesophageal Reflux Disease (GERD)MedDRA version: 8.1Level: LLTClassification code 10017924Term: Gastroesophageal reflux
EUCTR2006-004501-25-BEAstraZeneca AB30
进行中（未招募）
不适用
A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (TLESRs) in GERD patients with incomplete response to PPI - n.a.
EUCTR2006-004501-25-NLAstraZeneca AB30